Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape
James G Krueger
*
, John Frew
, Gregor B E Jemec
, Alexa B Kimball
, Brian Kirby
, Falk G Bechara
, Kristina Navrazhina
, Errol Prens
, Kristian Reich
, Eva Cullen
, Kerstin Wolk
*
Corresponding author for this work
Dermatology
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape'.
Sort by
Weight
Alphabetically
Keyphrases
Treatment Landscape
100%
Disease Mechanisms
100%
Hidradenitis Suppurativa
100%
Clinical Trials
28%
Interleukin-17 (IL-17)
28%
Abscess
14%
Disease Phenotype
14%
Treatment Options
14%
Hormonal Therapy
14%
Clinical Response
14%
Phase I Trial
14%
Treatment Outcome
14%
Mechanism of Action
14%
Topical Therapy
14%
Well-defined
14%
Tumor Necrosis Factor-α
14%
Adalimumab
14%
Unmet Needs
14%
Systemic Therapy
14%
Surgical Procedures
14%
Disease Management
14%
Phase II Trial
14%
Data Collection Methods
14%
Diagnostic Delay
14%
Therapeutic Potential
14%
Inflammatory Diseases
14%
Anogenital
14%
Gluteal
14%
U.S. Food
14%
Diagnosis Management
14%
Therapeutic Target
14%
Window of Opportunity
14%
European Medicines Agency
14%
Tissue Destruction
14%
Therapeutic Window
14%
Anti-tumor Necrosis Factor Antibody
14%
Distinct Mechanism
14%
Unmet Medical Need
14%
Geographical Location
14%
Rapidly Evolving
14%
Systemic Antibiotic Therapy
14%
Major Challenges
14%
Standardised Outcome Measures
14%
Acne Inversa
14%
Janus Kinase-signal Transducer
14%
Promising Therapeutics
14%
Disease Biomarkers
14%
Medicine and Dentistry
Hidradenitis Suppurativa
100%
Diseases
100%
Clinical Trial
37%
Interleukin 17
25%
Abscess
12%
Biological Marker
12%
Hormone Therapy
12%
Surgical Technique
12%
Cytokine
12%
Prevalence
12%
Adalimumab
12%
Antibiotic Therapy
12%
Pathophysiology
12%
Systemic Therapy
12%
Disease Management
12%
Janus Kinase
12%
Inflammatory Disorder
12%
Diagnostic Delay
12%
Topical Agent
12%
Tumor Necrosis
12%
Scar Formation
12%
Therapeutic Window
12%
Retinoid
12%
Tumor Necrosis Factor Antibody
12%
Phase III Trials
12%
Treatment Option
12%
Treatment Outcome
12%
Inflammation
12%
Therapeutic Target
12%
Pharmacology, Toxicology and Pharmaceutical Science
Suppurative Hidradenitis
100%
Diseases
100%
Clinical Trial
42%
Interleukin 17
28%
Prevalence
14%
Cytokine
14%
Inflammation
14%
Antibiotics
14%
Biological Marker
14%
Hormone Cancer Therapy
14%
Pathophysiology
14%
Janus Kinase
14%
Acne
14%
Adalimumab
14%
Abscess
14%
Inflammatory Disease
14%
Topical Agent
14%
Retinoid
14%
Tumor Necrosis
14%
Scar Formation
14%
Therapeutic Window
14%
Tumor Necrosis Factor Antibody
14%
Phase III Trials
14%